The Food and Drug Administration has approved a new combination medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved this year. The approval of Zerbaxa is the second antibiotic approval this year for Cubist Pharmaceuticals, which agreed earlier this month to be acquired for $8.4 billion by the world's fourth-biggest drug maker, Merck & Co.